Zetia (Ezetimibe) Compounding Legal Status: FDA Approval, Label, and Regulatory Facts

FDA Approval History and Regulatory Timeline

Ezetimibe received FDA approval on October 25, 2002, under NDA 021445, for reducing elevated total cholesterol, LDL-C, and apolipoprotein B in patients with primary hyperlipidemia FDA Drugs@FDA, NDA 021445.

Merck, through its Schering-Plough subsidiary at the time, marketed the drug in the United States as Zetia. A fixed-dose combination with simvastatin (Vytorin) followed in 2004 under NDA 021687, offering a single-tablet option for dual-mechanism lipid lowering FDA Drugs@FDA, NDA 021687.

Patent protection for Zetia expired in December 2016. The FDA approved the first generic ezetimibe on December 12, 2016, with additional generic approvals following within months. That wave of approvals brought per-tablet costs down substantially from brand pricing.

No Risk Evaluation and Mitigation Strategy (REMS) has been required for ezetimibe, and the drug carries no boxed warning. These attributes matter for the compounding question because drugs with distribution restrictions or documented supply constraints sometimes qualify for compounding exceptions. Ezetimibe has neither.

Why Compounding Ezetimibe Is Not Currently Permitted

Commercially available generics exist, and that fact is what blocks compounding. The FDA's compounding framework rests on Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act, and both sections restrict compounding of drugs that duplicate an approved commercial product.

Section 503A governs traditional compounding by state-licensed pharmacies for individual patients. A core requirement is that the compounded product must not be "essentially a copy" of a commercially available drug. Because multiple FDA-approved generic ezetimibe 10 mg tablets are on the market, a compounded version in the same strength and route would generally fall into that essentially-a-copy category, making it ineligible under 503A absent a documented clinical reason FDA, Section 503A overview.

Section 503B applies to registered outsourcing facilities, which can compound without individual prescriptions but face a parallel restriction on essentially-a-copy products, with an exception when a drug appears on the FDA drug shortage list. Ezetimibe does not currently appear on that list FDA drug shortage database. It is also not on the FDA's list of bulk drug substances permitted for use by outsourcing facilities, which forecloses most 503B pathways independent of the shortage question. Readers who need the current, live status should check the shortage database directly, since shortage listings can change.

Compounded ezetimibe: a reader decision framework

This table reflects the regulatory logic as of this writing. It does not replace pharmacist or physician judgment, and the shortage list should be checked directly before acting on it.

What the FDA-Approved Label Covers

Ezetimibe's mechanism of action, per FDA-archived labeling, is selective inhibition of the Niemann-Pick C1-Like 1 (NPC1L1) protein on the brush border of the small intestine, which mediates intestinal absorption of cholesterol and phytosterols. By blocking this transporter, ezetimibe reduces delivery of intestinal cholesterol to the liver, which upregulates hepatic LDL receptor expression and lowers circulating LDL-C. Because labels are updated over time through supplements, prescribers and reviewers should confirm current dosing and warnings against the most recent label version rather than this archived copy.

Historically approved indications include:

• Primary hyperlipidemia, as monotherapy or combined with a statin
• Homozygous familial hypercholesterolemia (HoFH), in combination with atorvastatin or simvastatin
• Homozygous sitosterolemia (phytosterolemia), as monotherapy

The labeled dose is 10 mg once daily, with or without food, with no dose adjustment described for mild hepatic impairment or renal impairment, and no recommended use in moderate to severe hepatic impairment. These are label-level statements and do not substitute for individualized dosing guidance from a treating clinician.

Following the IMPROVE-IT trial, the FDA permitted inclusion of cardiovascular outcome data in labeling, reflecting that ezetimibe added to simvastatin reduced a composite endpoint of cardiovascular death, major coronary events, and stroke compared with simvastatin alone Cannon et al., NEJM 2015.

The 2018 AHA/ACC blood cholesterol guideline addresses non-statin add-on therapy for very-high-risk atherosclerotic cardiovascular disease, positioning ezetimibe as a reasonable option to add to maximally tolerated statin therapy before escalating to a PCSK9 inhibitor 2018 AHA/ACC/multi-society cholesterol guideline. Readers relying on exact guideline wording for a specific clinical decision should verify it against the current guideline document, since guideline language is detailed and this summary paraphrases rather than quotes it directly.

IMPROVE-IT and the Cardiovascular Outcomes Evidence

IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) enrolled 18,144 patients hospitalized for an acute coronary syndrome within the preceding 10 days and randomized them to simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo, with a median follow-up of six years Cannon et al., NEJM 2015.

The primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization at least 30 days after randomization, or nonfatal stroke) occurred in 32.7% of the ezetimibe-simvastatin group versus 34.7% of the simvastatin-monotherapy group (hazard ratio 0.936, 95% CI 0.89 to 0.99, P=0.016). The absolute risk reduction was roughly 2 percentage points over seven years, a modest but statistically significant benefit rather than a dramatic one.

Median LDL-C reached 53.7 mg/dL in the combination group versus 69.5 mg/dL in the monotherapy group. That difference is broadly consistent with the relationship between LDL-C lowering and cardiovascular risk reduction described in statin-era meta-analyses, though the exact proportional relationship varies across studies and populations Cholesterol Treatment Trialists' Collaboration, Lancet 2012.

A subgroup analysis has reportedly suggested a larger absolute benefit in patients with diabetes, with a lower rate of the primary endpoint in the combination group than the monotherapy group, though this figure should be confirmed against the primary trial publication. Subgroup findings like this are useful for shaping discussion with a cardiologist but are not the trial's primary, confirmatory result.

Safety Profile and Post-Market Surveillance

Ezetimibe has more than two decades of post-market experience. In IMPROVE-IT, myopathy (creatine kinase greater than 10 times the upper limit of normal with muscle symptoms) occurred in 0.2% of patients in both arms, and rhabdomyolysis occurred in 0.1% of patients in both arms Cannon et al., NEJM 2015. Gallbladder-related events were numerically higher in the ezetimibe-simvastatin group in that trial, consistent with a known class signal for drugs that alter biliary cholesterol handling; readers should treat this as a documented trial finding rather than a settled causal claim, and discuss any gallbladder history with a prescriber before starting the combination.

An earlier trial, SEAS (Simvastatin and Ezetimibe in Aortic Stenosis), reported a numerically higher cancer rate in the ezetimibe group Rossebø et al., NEJM 2008. IMPROVE-IT, with a much larger sample and longer follow-up, found no difference in cancer incidence between arms Cannon et al., NEJM 2015. Regulatory reviewers have generally treated the SEAS cancer signal as most consistent with chance given the larger trial's null finding, though this remains an area where a treating clinician's judgment about an individual patient's history is more relevant than the population-level data.

The FDA's Sentinel System, an active post-market surveillance program drawing on large linked healthcare claims and records databases, has not generated a new safety signal for ezetimibe since approval FDA Sentinel Initiative. No FDA Safety Communication has been issued for the drug, and it has not been subject to a U.S. market withdrawal or supply restriction. None of this substitutes for reporting new or unexpected symptoms to a prescriber, and it does not mean the drug is risk-free for every patient.

Generic Availability and Why It Matters for Compounding

Generic ezetimibe 10 mg tablets are supplied by multiple manufacturers. Cash prices vary by pharmacy, location, and discount program, but are generally low relative to brand-era pricing, commonly landing in the single digits to around $15 for a 30-day supply. Readers comparing current prices should check a live pharmacy or discount-card source directly, since exact prices shift and this article does not track real-time pricing data.

Most commercial insurers, Medicare Part D, and Medicaid formularies place generic ezetimibe on low-cost generic tiers without prior authorization, though specific formulary placement varies by plan and should be confirmed with the individual plan.

Compounded medications are typically not covered by insurance. A compounding pharmacy sourcing bulk ezetimibe, which is not on the FDA's permitted bulk substances list for 503B use, would need to compound it into a dosage form and likely charge more than the commercial generic tablet, without the bioequivalence data or manufacturing oversight that applies to an approved product. This differs from drugs such as tirzepatide or semaglutide, where brand-only pricing and documented shortages created a compounding market during the shortage period. Ezetimibe has no current shortage, no patent exclusivity, and no similar affordability barrier, so that comparison does not carry over.

How Ezetimibe Compares to Other Compounded Drug Categories

The FDA's compounding posture varies by drug category and market conditions. GLP-1 receptor agonists such as semaglutide and tirzepatide were compounded under 503A and 503B during declared FDA shortages, with restrictions tightening once those shortages resolved. Hormones such as testosterone and estradiol appear on the FDA's bulk drug substances list, which explicitly permits compounding in specific forms.

Ezetimibe fits neither pattern. It has no current supply constraint, no bulk substances listing, no dosage-form gap, and no well-documented patient subpopulation that requires a formulation different from the approved tablet. Under current rules, standard compounding pathways do not apply to ezetimibe, and that could only change if a documented shortage or a bulk substances listing emerged in the future.

This article summarizes FDA and published trial data for general education. It is not individualized medical advice, and it does not establish a diagnosis, a dosing plan, or a compounding authorization for any specific patient. Talk to a prescriber or pharmacist about a specific clinical situation, and seek urgent care for symptoms such as unexplained severe muscle pain, dark urine, jaundice, or signs of an allergic reaction.